A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability, and Pharmacodynamics of JNJ-54175446 in Subjects With Major Depressive Disorder

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability, and Pharmacodynamics of JNJ-54175446 in Subjects With Major Depressive Disorder

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Jul 2017

At a glance

  • Drugs JNJ 54175446 (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 27 Jun 2017 Status changed from recruiting to completed.
    • 10 Jun 2017 Biomarkers information updated
    • 20 Feb 2017 Planned End Date changed from 1 Jul 2017 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top